Blog

  • RestoPros of Boise Expands Damage Restoration Services to Better Serve Customers

    RestoPros of Boise Expands Damage Restoration Services to Better Serve Customers

    MERIDIAN, ID – November 18, 2025 – PRESSADVANTAGE –

    RestoPros of Boise has announced the expansion of its comprehensive damage restoration services across the entire Treasure Valley area, reinforcing its commitment to providing emergency response capabilities to residential and commercial property owners throughout the region. The expansion ensures that certified restoration professionals are available around the clock to address water, fire, mold, and storm damage incidents across multiple communities.

    The company’s expanded service coverage now encompasses Boise, Caldwell, Eagle, Emmett, Garden City, Kuna, Melba, Meridian, Middleton, Nampa, Star, and surrounding areas within the Treasure Valley. This strategic expansion allows the restoration company to deploy emergency response teams more efficiently while maintaining the rapid response times critical during property damage emergencies.

    RestoPros of Boise Truck

    “Property damage from water, fire, or storms requires immediate professional attention to minimize long-term impacts and restoration costs,” said Brett Bowman, spokesperson for RestoPros of Boise. “Our expansion throughout the Treasure Valley means more families and businesses can access certified damage restoration services within the critical first hours following a disaster, which significantly affects the overall recovery process and timeline.”

    The company maintains a 24-hour emergency response capability, with teams equipped to handle initial damage assessment through complete restoration. Services include water extraction and drying, fire and smoke damage cleanup, mold detection and remediation, and storm damage repairs. Each restoration project follows Industry Institute of Cleaning and Restoration Certification (IICRC) guidelines, ensuring standardized procedures and quality outcomes.

    With 30 years of combined industry experience, the restoration professionals utilize advanced equipment and techniques for moisture detection, structural drying, and contamination control. The company’s mold remediation protocols include containment procedures to prevent spore spread during cleanup, while fire restoration services address both visible damage and hidden smoke contamination that can affect indoor air quality.

    “The expansion allows us to better serve the growing Treasure Valley region while maintaining the personalized service approach that property owners need during stressful situations,” added Bowman. “Whether dealing with a burst pipe in a Meridian office building or storm damage to a Nampa residence, our teams bring the same level of expertise and urgency to every restoration project.”

    The company provides free initial inspections and detailed restoration quotes to property owners experiencing damage. Restoration technicians assess structural integrity, moisture levels, and contamination risks to develop comprehensive mitigation plans tailored to each situation.

    RestoPros of Boise operates as a certified and insured restoration company specializing in emergency water damage and fire restoration services. The company serves both residential and commercial clients throughout the Treasure Valley area, providing round-the-clock emergency response for water extraction, fire and smoke cleanup, mold remediation, and storm damage restoration. The organization maintains certification through industry standards and employs restoration professionals with extensive experience in property damage mitigation and recovery.

    ###

    For more information about RestoPros of Boise, contact the company here:

    RestoPros of Boise
    Brett Bowman
    (208) 315-8811
    boise@restopros.co
    880 E Franklin Rd #308, Meridian, ID 83642

  • OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

    OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

    OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer.

    TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology.

    Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma.

    To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to experimental therapies that have the potential to treat these diseases. In the United States, a rare disease is defined as any condition that affects fewer than 200,000 patients. After granting Orphan Drug Designation, the US FDA qualifies companies or drug developers incentives such as tax credits for clinical trials, exemption from user fees, and marketing exclusivity2.

    In August 2025, OBI launched a phase I/II clinical trial in the United States and Taiwan, recruiting patients with advanced solid tumors. The objectives of the trial are to study the safety, pharmacokinetics, and preliminary efficacy profile of OBI-902 in these patient populations.

    Heidi Wang, Ph.D, OBI Pharma’s Chief Executive Officer noted, “Based on our preclinical data, OBI-902 has several important advantages over other TROP2 ADCs either approved or in development; including high stability in blood circulation, excellent bystander effect that extends the killing to neighboring cancer cells lacking TROP2 expression, potential ability to overcome drug resistance, and outstanding activity in animal and organoid models of cancer. Importantly, this marks the first time an ADC that incorporates OBI’s proprietary GlycOBI® ADC technology is being evaluated in patients, including those diagnosed with cholangiocarcinoma. We look forward to investigating this potential best-in-class TROP2 ADC in the clinic.”

    About OBI-902

    OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells and with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.

    OBI-902 is a novel site-specific glycan-conjugated ADC using OBI’s proprietary GlycOBI platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the US FDA on April 30, 2025.

    Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive, worldwide (except in China) license to a TROP2 targeting antibody amino acid sequence. Biosion holds exclusive rights to that antibody sequence in China. OBI holds worldwide commercial rights to OBI-902, except for the rights pertaining to the antibody in China.

    About GlycOBI®

    OBI has developed a unique clinical stage, glycan-based site-specific ADC technology (GlycOBI®), which is in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in drug-antibody ratio (DAR) up to 16. Utilizing OBI’s proprietary dual-function enzyme (EndoSymeOBI®) and linker technology (HYPrOBI®), homogenous ADCs are manufactured with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI’s linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI® conjugated ADCs have overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies. GlycOBI®, EndoSymeOBI®, and HYPrOBI® are part of the armamentarium of OBI’s Obrion™ ADC Enabling Technologies that also include ThiOBI® and GlycOBI DUO™. OBI-902 is the first ADC utilizing OBI’s Obrion™ ADC enabling technology for evaluation of safety and efficacy in Cancer, currently under Phase I/II clinical trial in the US and Taiwan.

    About OBI Pharma

    OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel therapeutic agents for patients with high unmet medical needs.

    OBI’s primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP2 ADC, OBI-992. Using the company’s proprietary ADC enabling technology, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI®; OBI has created its next-generation novel ADC pipeline, including monospecific: OBI-902 (TROP2), OBI-904 (Nectin-4), bispecific single payload (HER2 x TROP2), and bispecific, dual payload (cMET x HER3) ADCs. To broaden the applicability of linker technology, HYPrOBI®, OBI further developed a novel ThiOBI® platform to enable irreversible cysteine-based conjugation. Additionally, OBI’s pipeline includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at www.obipharma.com.

    GlycOBI®, EndoSymeOBI®, ThiOBI® and HYPrOBI®are registered trademarks of OBI Pharma. Obrion™ and GlycOBI DUO™ are trademarks under registration.

    1National Institute of Health for Rare Diseases. Sept. 2025

    https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma

    2US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

    Forward-Looking Statements

    Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.

    COMPANY CONTACT:
    Kevin Poulos, Chief Business Officer
    OBI Pharma USA, Inc.
    +1 (619) 537 7698, ext. 102
    kpoulos@obipharma.com

    SOURCE: OBI Pharma USA, Inc.

    View the original press release on ACCESS Newswire

  • Graid Technology Finalizes Intel VROC Licensing Agreement, Expanding Leadership in Enterprise Storage Solutions

    Graid Technology Finalizes Intel VROC Licensing Agreement, Expanding Leadership in Enterprise Storage Solutions

    SUNNYVALE, CALIFORNIA / ACCESS Newswire / November 17, 2025 / Graid Technology today announced the successful completion of its agreement with Intel Corporation to license the rights to market, sell, and develop Intel® Virtual RAID on CPU (Intel® VROC). The successful completion of this transaction marks a significant milestone that accelerates Graid Technology’s progress toward profitable growth and delivering on its vision for the future of enterprise storage.

    “This agreement represents an exciting new chapter for Graid Technology and for the global ecosystem that relies on Intel® VROC,” said Leander Yu, CEO of Graid Technology. “Finalizing the deal allows us to ensure long term continuity for existing customers while also accelerating innovation and value creation across the enterprise storage market.”

    Since the initial announcement, Graid Technology has engaged in productive discussions with many VROC customers, OEMs, and channel partners who have expressed strong support and enthusiasm for the transition.

    “Customer response has been overwhelmingly positive,” added Thomas Paquette, Sr. Vice President and GM, Americas & EMEA at Graid Technology. “Partners and system builders see this transition as a win win; protecting their current investments in Intel® VROC while benefiting from Graid Technology’s focus, agility, and commitment to high performance storage innovation.”

    Under the terms of the agreement, Graid Technology has assumed responsibility for Intel® VROC customer support and development pipeline, ensuring uninterrupted service and expanding collaboration opportunities across new storage and data infrastructure markets. At this time, Graid Technology has not established a roadmap for new feature enhancements to Intel® VROC, but the team is actively listening to customer feedback and prioritizing their ongoing needs.

    For more information about Intel® VROC and Graid Technology’s enterprise storage solutions, visit https://graidtech.com/vroc.

    Media Inquiries:
    Andrea Eaken
    Graid Technology Sr. Director of Marketing, Americas & EMEA
    andrea.eaken@graidtech.com

    Contact Information
    Andrea Eaken
    Senior Director of Marketing, Americas & EMEA
    andrea.eaken@graidtech.com
    949-742-9928

    .

    SOURCE: Graid Technology Inc.

    Related Images

    View the original press release on ACCESS Newswire

  • Avel eCare Specialty Clinic Surpasses 100,000 Patient Encounters, Expanding Access to Specialty Care Across Rural America

    Avel eCare Specialty Clinic Surpasses 100,000 Patient Encounters, Expanding Access to Specialty Care Across Rural America

    SIOUX FALLS, SD / ACCESS Newswire / November 18, 2025 / Avel eCare announced a landmark achievement this week as its Specialty Clinic service line officially surpassed 100,000 patient encounters – marking a major milestone in the company’s mission to deliver equitable specialty care to rural, remote, and underserved communities across the United States.

    Launched in 2017, Avel eCare Specialty Clinic provides virtual access to specialists in cardiology, psychiatry, dermatology, endocrinology, rheumatology, and more. The service has transformed access to care for thousands of patients in rural and underserved areas, helping health systems expand specialty access and improve outcomes through innovative virtual care delivery.

    “Reaching 100,000 patient encounters represents far more than a number – it represents lives changed,” said Dr. Kelly Rhone, Chief Medical Officer at Avel eCare. “Each encounter is a moment where a patient receives timely, expert care that might otherwise have been out of reach. We’re honored to serve as a trusted partner for clinicians and patients across the country.”

    Through Avel eCare Specialty Clinic, patients gain access to trusted specialists without leaving their local facilities, saving time, reducing costs, and improving outcomes. Hospitals and health systems benefit from expanded coverage, workforce stabilization, and real-time scheduling that helps reduce no-show rates.

    Since its inception, Avel’s Specialty Clinic team has become a proof-of-concept for how the Virtual Health System can drive lasting health equity, delivering measurable improvements in access, satisfaction, and clinical outcomes:

    • 100,000+ patient encounters delivered virtually

    • Five states served through long-term partnerships with Tribal Health organizations

    • Significant reductions in travel time and costs for rural patients

    “This milestone demonstrates what’s possible when innovation meets compassion,” said Doug Duskin, Chief Executive Officer at Avel eCare. “We’ve shown that telemedicine isn’t just a backup option – it’s a proven, effective model of care that strengthens communities, supports clinicians, and saves lives.”

    “Behind every one of those 100,000 encounters is a story of access, connection, and collaboration,” said Rachel Dybvig, MBA, Director of Avel eCare Specialty Clinic. “Our providers have built meaningful, ongoing relationships with patients who now have consistent access to specialty care – many for the first time in their lives. That’s the real impact of this milestone.”

    Avel eCare’s Specialty Clinic remains committed to advancing equitable access to specialty care, with ongoing growth across new specialties and regions. The program continues to expand its impact through collaboration with hospitals, clinics, and health systems nationwide – redefining what’s possible in virtual clinical care.

    About Avel eCare

    Avel eCare is one of the nation’s longest-standing telemedicine providers and a pioneer in the development of the Virtual Health System model. For more than 30 years, Avel has delivered high-quality, technology-enabled care across a wide range of clinical specialties, including emergency and critical care, behavioral health, pharmacy, and specialty medicine. Guided by a mission to improve access, quality, and equity of care, Avel eCare continues to lead the way in transforming how healthcare is delivered, wherever patients and providers need support.

    Contact:

    Jessica Gaikowski, Director of Marketing & Communications
    media@avelecare.com | 605.606.0150

    Learn more at www.avelecare.com

    SOURCE: Avel eCare

    View the original press release on ACCESS Newswire

  • Hyland and Tribun Health Partner to Deliver Next-Generation, Intelligent Digital Pathology

    Hyland and Tribun Health Partner to Deliver Next-Generation, Intelligent Digital Pathology

    Hyland expands its Enterprise Imaging portfolio with an agentic digital pathology platform that simplifies diagnostic workflows, enhances collaboration, and improves outcomes across health organizations worldwide.

    CLEVELAND, OH / ACCESS Newswire / November 18, 2025 / Hyland, the pioneer of the Content Innovation Cloud™, and Tribun Health, a leader in digital pathology, have joined forces to advance pathology workflows by integrating Tribun Health’s advanced platform with Hyland’s enterprise imaging solutions. This synergy puts cutting-edge AI and digital technology at the core of diagnostics, enabling pathologists to work faster and smarter.

    Digital Oncology Case Review in the Pathology Lab
    Digital Oncology Case Review in the Pathology Lab
    A pathologist reviews a case in the lab using CaloPix, examining whole slide images through a modern digital pathology platform. The scene highlights the precision, consistency, and efficiency enabled by enterprise-grade diagnostic workflows.

    “This partnership between Hyland and Tribun Health positions healthcare organizations at the forefront of agentic digital pathology,” said Michael Campbell, chief product officer at Hyland. “Together, we’re setting a new standard for data-driven diagnostics, delivering faster, more precise diagnoses and improving patient outcomes; while reinforcing our shared commitment to driving innovation in healthcare.”

    “Pathology workflows are notoriously intricate, with massive datasets, critical timelines, and frequent collaboration requirements,” said Jean-François Pomerol, CEO at Tribun Health. “By combining Tribun Health’s leading AI pathology platform, CaloPix®, with Hyland’s proven enterprise imaging capabilities, we’re advancing an end-to-end solution that addresses these intricacies by enabling healthcare organizations to dramatically transform their workflow and diagnostic capabilities.”

    Delivering better patient experiences with digital pathology

    This all-new solution aggregates and archives digital pathology gross images and whole slide images (WSI) alongside radiology, cardiology, and other imaging specialties, providing clinicians with a single, comprehensive view of each patient’s complete imaging record. Key benefits include:

    Advanced Integration: Hyland’s comprehensive enterprise imaging solutions, including Acuo vendor neutral archive (VNA) and NilRead will be designed to integrate with pathology solutions from Tribun Health, including its smart MacroCam, CaloPix platform, and diagnostics applications to radically improve digital pathology workflow efficiency and consistency.

    Optimized Workflows: This combined solution will enable cross-disciplinary collaboration between pathology, radiology, and other specialties while integrating multi-format medical imaging under one unified system.

    Future-Forward Technology: Support for Digital Imaging and Communications in Medicine (DICOM) standardization in pathology imaging and AI-driven diagnostics positions healthcare providers to advance research and enhance clinical decision-making.

    “The integration of Hyland’s enterprise medical imaging solutions with Tribun Health’s AI pathology platform reflects a meaningful progression in data-driven diagnostics,” said Mutaz Shegewi, senior research director, worldwide healthcare provider AI, platforms and technologies at IDC. “By unifying medical imaging and digital pathology workflows within an intelligent, interoperable framework, this partnership addresses key challenges in diagnostic speed, accuracy, and collaboration. It illustrates how AI and advanced medical imaging can work together to enhance clinical efficiency and support improved patient outcomes.”

    Hyland Healthcare delivers connected, agentic solutions that unlock the value of unstructured content and medical imaging across healthcare enterprises. By integrating seamlessly with core systems like EMRs, Hyland’s platform consolidates documents, images, and clinical data into a single, intelligent workflow; streamlining operations, accelerating diagnoses, and empowering providers to make smarter, faster decisions that improve patient outcomes. Trusted by over half of U.S. health systems, Hyland’s solutions support interoperability, automation, and scalability to meet the evolving demands of modern healthcare.

    The future of enterprise imaging starts here. Explore Hyland + Tribun Health’s intelligent digital pathology at RSNA 2025 — Booth #1322, McCormick Place.

    For more information on Hyland’s platform and solutions, please visit Hyland.com.

    About Hyland  

    Hyland empowers organizations with unified content, process and application intelligence solutions, unlocking profound insights that fuel innovations. Trusted by thousands of organizations worldwide, including many of the Fortune 100, Hyland’s solutions fundamentally redefine how teams operate and engage with those they serve. For more information on Hyland, our products and solutions, please visit Hyland.com.

    About Tribun Health

    Tribun Health is a global leader in digital pathology, delivering the Best in KLAS award-winning platform CaloPix®, which is CE-marked, Health Canada-approved, and FDA-cleared for clinical use. Its pathology solutions help enhance workflow efficiency, diagnostic accuracy, and patient outcomes. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovation, Tribun Health is shaping the future of cancer care. For more information, visit Tribun Health.

    Media contact:

    Jason Gerdon  | jason.gerdon@hyland.com

    Contact Information

    Andreia Beyer
    VP, Global Marketing & Managing Director, North America
    abeyer@tribun.health
    +1 (416) 565-0474

    .

    SOURCE: Tribun Health

    View the original press release on ACCESS Newswire

  • Leading SEO Agency Lex Digital Recognized for Legal Sector Marketing Excellence in Belgium

    Leading SEO Agency Lex Digital Recognized for Legal Sector Marketing Excellence in Belgium

    ANTWERPEN, BELGIUM – November 18, 2025 – PRESSADVANTAGE –

    Lex Digital, the Antwerp-based digital marketing firm specializing in search engine optimization and AI-powered marketing solutions, has been recognized as Best Legal Sector Marketing Specialists 2025 in Belgium.

    The award acknowledges the firm’s distinctive approach to serving law firms and legal professionals through specialized digital marketing strategies that combine technical SEO expertise with deep understanding of the legal sector. The recognition and positive feedback from clients has led to Bart Gagelmans, Founder of Lex Digital, being invited to participate in the Flemish Bar Association’s digital marketing panel on November 17, 2025, during the Week of the Entrepreneur.

    Lex Digital

    “This recognition validates our unique position in the market where legal expertise meets digital innovation,” said Bart Gagelmans. “Having studied law myself before specializing in digital marketing, I understand the specific challenges law firms face in building their online presence while maintaining professional standards and client trust.”

    The recognition came as the company’s founder, Bart Gagelmans, shared his expertise as a panel speaker during a YouTube Live session about marketing hosted by the Flemish Bar Association. The panel discussion covered practical considerations for legal professionals navigating digital marketing, including channel selection, the value of external marketing support, and authentic positioning strategies for Belgian law firms in the digital landscape. The session formed part of the Flemish Bar Association’s initiative to provide lawyers with contemporary business development tools and insights.

    The company, founded in 2023, has distinguished itself by offering guaranteed top rankings in both traditional Google search results and emerging AI-powered search platforms within 12 months. This confidence stems from the firm’s structured four-step methodology that includes comprehensive analysis, tailored strategy development, transparent execution tracking, and continuous data-driven optimization.

    Lex Digital’s client portfolio has expanded beyond the legal sector to include construction businesses, IT, and B2B services. The firm has maintained a remarkable 100 percent client retention rate since its founding, demonstrating the effectiveness of its long-term partnership approach.

    “The legal profession is experiencing a digital transformation, and firms that adapt their marketing strategies accordingly are seeing substantial growth,” added Gagelmans. “One of our law firm clients grew from two to nine lawyers within a single year through strategic SEO implementation, demonstrating the tangible impact of effective digital marketing.”

    The firm has positioned itself at the forefront of AI SEO optimization, developing proprietary tracking tools to monitor performance across AI chat platforms, including ChatGPT and Google’s AI overviews. This forward-thinking approach addresses the evolving search landscape where AI-powered results increasingly influence how potential clients discover and evaluate legal services.

    Lex Digital operates from Antwerp, serving clients throughout Belgium and the Netherlands with services encompassing SEO, AI SEO, search engine advertising, copywriting, and public relations. The company’s approach emphasizes measurable results through real-time performance dashboards and transparent reporting systems that allow clients to track their digital marketing investments’ return.

    ###

    For more information about Lex Digital, contact the company here:

    Lex Digital
    Bart Gagelmans
    +32 493 29 27 43
    info@lexdigital.be
    Lex Digital
    Brusselstraat 51
    2018 Antwerpen, Belgium

  • B&Bowa’s Cleaning Services Wins 2025 Consumer Choice Award for Residential & Commercial Cleaning in Regina

    B&Bowa’s Cleaning Services Wins 2025 Consumer Choice Award for Residential & Commercial Cleaning in Regina

    REGINA, SK / ACCESS Newswire / November 18, 2025 / B&Bowa’s Cleaning Services, one of Saskatchewan’s top-rated and most trusted cleaning companies, has won the 2025 Consumer Choice Award in the Residential & Commercial Cleaning Services category for Regina. This recognition honours B&Bowa’s dedication to transforming homes, businesses, and industrial facilities into spotless, healthy environments with care, consistency, and exceptional service.

    Founded in 2016 by a dedicated husband-and-wife team, B&Bowa’s Cleaning has grown from a small home-based operation into a full-scale company trusted by families and businesses across Regina and surrounding areas.

    A Local Success Story Built on Clean Results

    What started as a passion for spotless homes and happy clients has become a thriving cleaning company that now maintains over 150 homes and millions of square feet of commercial space every month. Today, B&Bowa’s Cleaning is powered by a team of 45 full-time and 20 part-time professional cleaners who share the same commitment to delivering quality and peace of mind.

    “Winning the Consumer Choice Award is an incredible honour for our entire team and a reflection of the trust our clients place in us every day,” said the B&Bowa’s Cleaning Services team. “Our mission is simple: deliver exceptional results every time, so our clients can focus on what matters most.”

    Complete Cleaning Solutions for Every Space

    B&Bowa’s Cleaning offers a wide range of services to meet the unique needs of residential, commercial, and industrial clients. Their trusted services include:

    • Commercial Cleaning: Regular janitorial services, nightly office cleaning, and common area maintenance.

    • Residential Cleaning: One-time deep cleans, scheduled home cleaning, move-in/move-out services, and custom house care.

    • Industrial Cleaning: Heavy-duty facility cleaning, floor maintenance for warehouses and production sites.

    • Post-Construction Cleanup: Detailed cleaning to remove dust and debris after renovations or new builds.

    • Disinfection and Sanitation: Thorough sanitizing solutions to maintain healthy spaces in homes and workplaces.

    • Window Cleaning: Interior and exterior window washing for homes and businesses.

    • Power Washing: High-pressure cleaning for exteriors, driveways, and building facades.

    • Garage and Parking Lot Cleaning: Clearing debris and maintaining clean, safe parking areas.

    • Carpet and Upholstery Cleaning: Deep cleaning services to refresh carpets, rugs, and furniture.

    Every service is delivered by trained professionals using high-quality products, advanced equipment, and proven methods to ensure top-tier results.

    A Dedicated Team You Can Trust

    At the heart of B&Bowa’s success is a dedicated, background-checked team that takes pride in making every space shine. Team members receive extensive training, follow detailed quality checklists, and undergo regular performance reviews to keep standards high.

    Clients appreciate the company’s open communication, consistent scheduling, and genuine respect for their homes and workplaces.

    Rooted in the Regina Community

    As a locally owned and operated company, B&Bowa’s Cleaning is deeply invested in the community it serves. The company creates good local jobs, supports local families, and values long-term relationships built on trust, transparency, and quality service.

    Word-of-mouth referrals and loyal clients have been key to B&Bowa’s steady growth and its reputation as a reliable partner for clean, healthy spaces.

    Raising the Bar for Clean, Year After Year

    With this Consumer Choice Award win, B&Bowa’s Cleaning Services plans to keep growing its skilled team, expand eco-friendly cleaning options, and invest in technology to make scheduling and communication even smoother for busy clients.

    One thing will never change: the founders’ promise to deliver spotless results, every time, so clients can focus on what truly matters – not the mess.

    To learn more about B&Bowa’s Cleaning Services or to get a personalized quote for your home, business, or facility, CLICK HERE or visit www.bbowascleaning.com.

    About Consumer Choice Award
    Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category win this prestigious recognition. Visit www.ccaward.com to learn more.

    Contact Information
    Sumi Saleh
    Communications Manager
    ssaleh@ccaward.com

    SOURCE: Consumer Choice Award

    View the original press release on ACCESS Newswire

  • Ginza Diamond Shiraishi Hong Kong Shares the Art and Craft Behind Its Diamond Ring Collections

    Ginza Diamond Shiraishi Hong Kong Shares the Art and Craft Behind Its Diamond Ring Collections

    HONG KONG, HK – November 18, 2025 – PRESSADVANTAGE –

    Ginza Diamond Shiraishi Hong Kong announces an in-depth overview of the cultural, structural, and craftsmanship foundations guiding the development of its 鑽石戒指 (diamond ring) collections. The brand has spent decades refining techniques and design philosophies that focus on symbolism, technical precision, and long-term durability. This announcement aims to provide a clear perspective on how the company interprets diamond ring artistry, the production methods behind each piece, and the traditional values that continue to influence its approach within Hong Kong.

    The company states that its commitment to clarity and craftsmanship begins with the belief that a diamond ring represents a lasting symbol rather than a decorative object. This principle forms the basis of the brand’s design and production structure. Each ring is conceptualized through detailed sketches, followed by modelling processes that allow artisans to evaluate proportions, strength, and overall visual balance. Every stage, including shaping, setting, polishing, and evaluating, is carried out with the intention of supporting both conceptual meaning and long-term structural stability.

    Ginza Diamond Shiraishi 鑽石戒指 (diamond ring)

    Ginza Diamond Shiraishi Hong Kong explains that its 銀座白石鑽石戒指 (Ginza Diamond Shiraishi diamond ring) designs are created through an approach that blends traditional Japanese craftsmanship with contemporary modelling accuracy, ensuring that each ring reflects both symbolic depth and technical refinement. This guiding framework shapes how the brand balances form, structure, and the interaction between metalwork and gemstones.

    Design principles from Japanese traditions play a significant role in shaping each ring’s structure and appearance. Many diamond ring designs integrate smooth curvature, subtle symmetry, and elements that suggest movement or progression. These details resonate with themes of continuity and refined simplicity. They are introduced to communicate the understated qualities valued in traditional Japanese aesthetics, where form and purpose must align naturally.

    The company highlights that material selection serves as a crucial foundation for creating its diamond rings. Platinum is frequently chosen due to its density, stability, and resistance to distortion. These characteristics support consistent long-term wear and structural reliability. Gold in various tones is also crafted for designs requiring specific visual interpretations or personal preferences. Regardless of the material selected, each piece undergoes multiple stages of inspection to confirm uniformity and structural accuracy.

    The crafting process continues through a sequence of specialised steps. After initial modelling, artisans refine each form through shaping, smoothing, and texturing. Surfaces are examined under magnification to ensure that angles, prongs, and structural points meet internal quality benchmarks. Rings containing diamonds are handed to stone setters who evaluate the optimal setting structure based on the stone’s size, shape, and cut. Each diamond is secured using techniques designed to support durability, clarity, and aesthetic harmony.

    Diamond selection follows internationally recognised assessment standards that include cut quality, clarity, internal structure, symmetry, and light performance. The company notes that emphasis is placed on the stone’s optical behaviour and structural consistency rather than size alone. Each diamond is observed under controlled conditions to evaluate its internal characteristics and to ensure compatibility with the intended ring structure.

    Ginza Diamond Shiraishi Hong Kong also underscores the importance of customization in creating meaningful diamond rings. Many couples seek features that represent personal experiences or shared milestones. The brand supports this through various customization options that may include adjusting band curvature, engraving dates or initials, modifying ring width, or selecting alternative stone arrangements. Semi-order and bespoke pathways are available for clients who prefer deeper involvement in the design structure from the early sketch stage to final refinement.

    Long-term wearability remains a central consideration in the company’s approach. Diamond rings are intended to accompany individuals during daily routines across many years, making maintenance essential. The company emphasises the importance of periodic inspections, professional cleaning, and size adjustments to maintain structural balance and comfort. Each ring is created with this extended timeline in mind, ensuring that its form remains as stable and consistent as possible.

    Within Hong Kong, the brand maintains an environment where individuals can examine diamond ring options through structured information rather than persuasive methods. Staff members explain metal properties, diamond evaluation factors, structural components, and origin points of design concepts. The environment is intended to support thoughtful and informed review without pressure, aligning with the brand’s commitment to clarity and education.

    The influence of Japanese craftsmanship remains a defining characteristic of the company’s identity. Techniques rooted in discipline, precision, and restraint guide how each ring is developed. Artisans follow a structured approach in which repetition of technique, careful observation, and respect for materials contribute to the final result. This ensures that each diamond ring reflects qualities associated with traditional Japanese artistry, including refinement, balance, and continuity.

    Through this announcement, Ginza Diamond Shiraishi Hong Kong reinforces its dedication to maintaining the traditions and technical standards that shape its 鑽石戒指 (diamond ring) collections. Each ring represents a combination of symbolic meaning, artisanal technique, structural consistency, and long-term consideration. The brand’s ongoing work continues to reflect a philosophy that values precision, purpose, and the cultural significance associated with jewellery designed for important life milestones.

    The company states that it will continue sharing insight into its craftsmanship principles as it develops its presence within Hong Kong’s bridal and fine jewellery landscape. Its objective is to preserve the values that have defined its approach since its early origins while supporting evolving expectations for clarity, durability, and design structure.

    For more information, visit:

    https://pressadvantage.com/story/85421-ginza-diamond-shiraishi-hong-kong-announces-updated-design-framework-for-wedding-rings-reflecting-mo

    ###

    For more information about Ginza Diamond Shiraishi Tsim Sha Tsui 銀座白石尖沙咀, contact the company here:

    Ginza Diamond Shiraishi Tsim Sha Tsui 銀座白石尖沙咀
    Mr. Shiraishi
    (852) 2668 0376
    admin@diamond-shiraishi.hk
    L319-L320, The ONE, 100 Nathan Road, Tsim Sha Tsui, Hong Kong

  • Atlas Salt to Begin Trading on OTCQX Under the Symbol “SALQF”

    Atlas Salt to Begin Trading on OTCQX Under the Symbol “SALQF”

    ST. GEORGE’S, NEWFOUNDLAND AND LABRADOR / ACCESS Newswire / November 17, 2025 / Atlas Salt Inc. (“Atlas Salt” or the “Company”) (TSXV:SALT)(OTCQX:SALQF) announces that, effective today, its shares will begin trading on OTCQX under the symbol “SALQF”. Its shares had previously traded on the OTCQB Venture Market under the symbol “REMRF”.

    The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

    Nolan Peterson, CEO of Atlas Salt, commented, “Moving to the OTCQX Market is an important step in making Atlas Salt’s shares more accessible to a broader market of investors. We believe the improved visibility, enhanced liquidity, and alignment with premier U.S. markets will significantly strengthen our accessibility to institutional and retail investors alike as we continue advancing the Great Atlantic Salt Project.”

    About OTC Markets Group Inc.

    OTC Markets Group Inc. (OTCQX) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

    About Atlas Salt

    Atlas Salt is developing North America’s next salt mine and is committed to responsible and sustainable mining practices. With a focus on innovation and efficiency, the company is poised to make significant contributions to the North American salt market while upholding its values of environmental stewardship and community engagement.

    For information, please contact:

    Jeff Kilborn, CFO & VP Corporate Development
    investors@atlassalt.com
    (709) 275-2099

    We seek safe harbour.

    Cautionary Statement

    Neither the TSX Venture Exchange nor its Regulation Services Provider, (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this press release relate to, among other things: obtaining financing, completion, delivery and timing of project components and requirements, and analysis and assumptions related thereto. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, technical, economic, and competitive uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing, completion and delivery of required permits, supply arrangements and financing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, the Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

    SOURCE: Atlas Salt Inc.

    View the original press release on ACCESS Newswire

  • Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities

    Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities

    New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network

    More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs

    CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to its existing Moderna Technology Center (“MTC”) in Norwood, Massachusetts. Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the U.S. This milestone marks a significant step in strengthening Moderna’s U.S. manufacturing network, supporting both commercial and clinical supply, and reinforcing the Company’s commitment to domestic mRNA production.

    “By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.,” said Stéphane Bancel, Chief Executive Officer of Moderna. “As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community.”

    The expansion reflects Moderna’s ongoing investment in U.S.-based infrastructure and its commitment to build a robust, domestic manufacturing platform capable of supporting its pipeline of mRNA vaccines and therapeutics. Moderna’s innovative mRNA platform, first widely recognized globally during the Company’s partnership with the U.S. Government through Operation Warp Speed, continues to drive potential biomedical breakthroughs across infectious diseases, cancer, rare diseases and autoimmune disorders.

    Construction at MTC for the new Drug Product manufacturing capability has started with Moderna targeting completion by the first half of 2027.

    About Moderna
    Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

    With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s U.S. manufacturing network and ongoing investment in U.S.-based infrastructure; the potential of Moderna’s mRNA platform; Moderna’s targeted completion of its new Drug Product manufacturing capability by the first half of 2027; and expected job creation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts
    Media:
    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire